Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dexin Kong

Showing results (1-10 of 169) with videos related to

Pageof 17
Sort By:
Bioorganic & Medicinal Chemistry|February 17, 2012
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugsDexin Kong, Takao Yamori
Cancer Science|July 12, 2008
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapyDexin Kong, Takao Yamori
Cancer Science|August 23, 2007
ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoformsDexin Kong, Takao Yamori
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 12, 2010
[Kinase inhibitors]Takao Yamori, Dexin Kong
Current Medicinal Chemistry|August 20, 2009
Advances in development of phosphatidylinositol 3-kinase inhibitorsDexin Kong, Takao Yamori
Journal of Integrative Plant Biology|September 20, 2019
UPA2 and ZmRAVL1: Promising targets of genetic improvement of maize plant architectureDexin Kong, Baobao Wang, Haiyang Wang
Biological & Pharmaceutical Bulletin|September 9, 2010
Discovery of phosphatidylinositol 3-kinase inhibitory compounds from the Screening Committee of Anticancer Drugs (SCADS) libraryDexin Kong, Kanami Yamazaki, Takao Yamori
Entropy (Basel, Switzerland)|December 3, 2020
Deep Common Semantic Space Embedding for Sketch-Based 3D Model RetrievalJing Bai, Mengjie Wang, Dexin Kong
Acta Pharmaceutica Sinica. B|January 26, 2017
Class I phosphatidylinositol 3-kinase inhibitors for cancer therapyWennan Zhao, Yuling Qiu, Dexin Kong
Frontiers in Pharmacology|June 6, 2022
Editorial: Chemo-Radiation-Resistance in Cancer TherapyXiaoping Lin, Dexin Kong, Zhe-Sheng Chen
Pageof 17

Showing results (1-10 of 169) with videos related to

Sort By:
Pageof 17
Bioorganic & Medicinal Chemistry|February 17, 2012
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugsDexin Kong, Takao Yamori
Cancer Science|July 12, 2008
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapyDexin Kong, Takao Yamori
Cancer Science|August 23, 2007
ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoformsDexin Kong, Takao Yamori
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 12, 2010
[Kinase inhibitors]Takao Yamori, Dexin Kong
Current Medicinal Chemistry|August 20, 2009
Advances in development of phosphatidylinositol 3-kinase inhibitorsDexin Kong, Takao Yamori
Journal of Integrative Plant Biology|September 20, 2019
UPA2 and ZmRAVL1: Promising targets of genetic improvement of maize plant architectureDexin Kong, Baobao Wang, Haiyang Wang
Biological & Pharmaceutical Bulletin|September 9, 2010
Discovery of phosphatidylinositol 3-kinase inhibitory compounds from the Screening Committee of Anticancer Drugs (SCADS) libraryDexin Kong, Kanami Yamazaki, Takao Yamori
Entropy (Basel, Switzerland)|December 3, 2020
Deep Common Semantic Space Embedding for Sketch-Based 3D Model RetrievalJing Bai, Mengjie Wang, Dexin Kong
Acta Pharmaceutica Sinica. B|January 26, 2017
Class I phosphatidylinositol 3-kinase inhibitors for cancer therapyWennan Zhao, Yuling Qiu, Dexin Kong
Frontiers in Pharmacology|June 6, 2022
Editorial: Chemo-Radiation-Resistance in Cancer TherapyXiaoping Lin, Dexin Kong, Zhe-Sheng Chen
Pageof 17